Cargando…

Statin use and risk of colorectal cancer in patients with inflammatory bowel disease

BACKGROUND: Statin use has been linked to a reduced risk of advanced colorectal adenomas, but its association with colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD) - a high risk population for CRC - remains inconclusive. METHODS: From a nationwide IBD cohort in Sweden, we id...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jiangwei, Halfvarson, Jonas, Bergman, David, Ebrahimi, Fahim, Roelstraete, Bjorn, Lochhead, Paul, Song, Mingyang, Olén, Ola, Ludvigsson, Jonas F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474364/
https://www.ncbi.nlm.nih.gov/pubmed/37662517
http://dx.doi.org/10.1016/j.eclinm.2023.102182
_version_ 1785100475857633280
author Sun, Jiangwei
Halfvarson, Jonas
Bergman, David
Ebrahimi, Fahim
Roelstraete, Bjorn
Lochhead, Paul
Song, Mingyang
Olén, Ola
Ludvigsson, Jonas F.
author_facet Sun, Jiangwei
Halfvarson, Jonas
Bergman, David
Ebrahimi, Fahim
Roelstraete, Bjorn
Lochhead, Paul
Song, Mingyang
Olén, Ola
Ludvigsson, Jonas F.
author_sort Sun, Jiangwei
collection PubMed
description BACKGROUND: Statin use has been linked to a reduced risk of advanced colorectal adenomas, but its association with colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD) - a high risk population for CRC - remains inconclusive. METHODS: From a nationwide IBD cohort in Sweden, we identified 5273 statin users and 5273 non-statin users (1:1 propensity score matching) from July 2006 to December 2018. Statin use was defined as the first filled prescription for ≥30 cumulative defined daily doses and followed until December 2019. Primary outcome was incident CRC. Secondary outcomes were CRC-related mortality and all-cause mortality. Cox regression estimated adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs). FINDINGS: During a median follow-up of 5.6 years, 70 statin users (incidence rate (IR): 21.2 per 10,000 person-years) versus 90 non-statin users (IR: 29.2) were diagnosed with incident CRC (rate difference (RD), −8.0 (95% CIs: −15.8 to −0.2 per 10,000 person-years); aHR = 0.76 (95% CIs: 0.61 to 0.96)). The benefit for incident CRC was duration-dependent in a nested case-control design: as compared to short-term use (30 days to <1 year), the adjusted odd ratios were 0.59 (0.25 to 1.43) for 1 to <2 years of use, 0.46 (0.21 to 0.98) for 2 to <5 years of use, and 0.38 (0.16 to 0.86) for ≥5 years of use (P(for tread) = 0.016). Compared with non-statin users, statin users also had a decreased risk for CRC-related mortality (IR: 6.0 vs. 11.9; RD, −5.9 (−10.5 to −1.2); aHR, 0.56 (0.37 to 0.83)) and all-cause mortality (IR: 156.4 vs. 231.4; RD, −75.0 (−96.6 to −53.4); aHR, 0.63 (0.57 to 0.69)). INTERPRETATION: Statin use was associated with a lower risk of incident CRC, CRC-related mortality, and all-cause mortality. The benefit for incident CRC was duration-dependent, with a significantly lower risk after ≥2 years of statin use. FUNDING: This research was supported by 10.13039/501100006636Forte (i.e., the 10.13039/501100006636Swedish Research Council for Health, Working Life and Welfare).
format Online
Article
Text
id pubmed-10474364
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104743642023-09-03 Statin use and risk of colorectal cancer in patients with inflammatory bowel disease Sun, Jiangwei Halfvarson, Jonas Bergman, David Ebrahimi, Fahim Roelstraete, Bjorn Lochhead, Paul Song, Mingyang Olén, Ola Ludvigsson, Jonas F. eClinicalMedicine Articles BACKGROUND: Statin use has been linked to a reduced risk of advanced colorectal adenomas, but its association with colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD) - a high risk population for CRC - remains inconclusive. METHODS: From a nationwide IBD cohort in Sweden, we identified 5273 statin users and 5273 non-statin users (1:1 propensity score matching) from July 2006 to December 2018. Statin use was defined as the first filled prescription for ≥30 cumulative defined daily doses and followed until December 2019. Primary outcome was incident CRC. Secondary outcomes were CRC-related mortality and all-cause mortality. Cox regression estimated adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs). FINDINGS: During a median follow-up of 5.6 years, 70 statin users (incidence rate (IR): 21.2 per 10,000 person-years) versus 90 non-statin users (IR: 29.2) were diagnosed with incident CRC (rate difference (RD), −8.0 (95% CIs: −15.8 to −0.2 per 10,000 person-years); aHR = 0.76 (95% CIs: 0.61 to 0.96)). The benefit for incident CRC was duration-dependent in a nested case-control design: as compared to short-term use (30 days to <1 year), the adjusted odd ratios were 0.59 (0.25 to 1.43) for 1 to <2 years of use, 0.46 (0.21 to 0.98) for 2 to <5 years of use, and 0.38 (0.16 to 0.86) for ≥5 years of use (P(for tread) = 0.016). Compared with non-statin users, statin users also had a decreased risk for CRC-related mortality (IR: 6.0 vs. 11.9; RD, −5.9 (−10.5 to −1.2); aHR, 0.56 (0.37 to 0.83)) and all-cause mortality (IR: 156.4 vs. 231.4; RD, −75.0 (−96.6 to −53.4); aHR, 0.63 (0.57 to 0.69)). INTERPRETATION: Statin use was associated with a lower risk of incident CRC, CRC-related mortality, and all-cause mortality. The benefit for incident CRC was duration-dependent, with a significantly lower risk after ≥2 years of statin use. FUNDING: This research was supported by 10.13039/501100006636Forte (i.e., the 10.13039/501100006636Swedish Research Council for Health, Working Life and Welfare). Elsevier 2023-08-24 /pmc/articles/PMC10474364/ /pubmed/37662517 http://dx.doi.org/10.1016/j.eclinm.2023.102182 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Articles
Sun, Jiangwei
Halfvarson, Jonas
Bergman, David
Ebrahimi, Fahim
Roelstraete, Bjorn
Lochhead, Paul
Song, Mingyang
Olén, Ola
Ludvigsson, Jonas F.
Statin use and risk of colorectal cancer in patients with inflammatory bowel disease
title Statin use and risk of colorectal cancer in patients with inflammatory bowel disease
title_full Statin use and risk of colorectal cancer in patients with inflammatory bowel disease
title_fullStr Statin use and risk of colorectal cancer in patients with inflammatory bowel disease
title_full_unstemmed Statin use and risk of colorectal cancer in patients with inflammatory bowel disease
title_short Statin use and risk of colorectal cancer in patients with inflammatory bowel disease
title_sort statin use and risk of colorectal cancer in patients with inflammatory bowel disease
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474364/
https://www.ncbi.nlm.nih.gov/pubmed/37662517
http://dx.doi.org/10.1016/j.eclinm.2023.102182
work_keys_str_mv AT sunjiangwei statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease
AT halfvarsonjonas statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease
AT bergmandavid statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease
AT ebrahimifahim statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease
AT roelstraetebjorn statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease
AT lochheadpaul statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease
AT songmingyang statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease
AT olenola statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease
AT ludvigssonjonasf statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease